Page 80 of 123: studies 791 to 800 of 1,225, newest first. Back to the esketamine overview
Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology October 30, 2016 Reji Thomas, Mesut Çetin, Glen B. Baker et al. 6 citations
-
Translational Psychiatry September 20, 2016 Daniel M. Rotroff, Daniel Corum, Alison A. Motsinger‐Reif et al. 99 citations
Ketamine, at sub-anesthetic doses, is reported to rapidly decrease depression symptoms in patients with treatment-resistant major depressive disorder (MDD). Many patients do not respond to currently available antidepressants, (for example, serotonin reuptake inhibitors), making ketamine and its enantiomer, esketamine, potentially attractive options for treatment-resistant MDD. Although...
Psychiatry Research May 30, 2016 Chun Yang, Mei Han, Ji-Chun Zhang et al.
Clinical use of the rapid antidepressant drug ketamine is limited, due to psychotomimetic side effects. R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to S-ketamine (esketamine), since it is free of psychotomimetic side effects. Repeated, intermittent administration of esketamine (10mg/kg, once per week for 8-weeks), but not R-ketamine, caused loss of...
April 20, 2016 Fangbo Lin, Deren Hou, Qiuping Tang 8 citations
OBJECTIVE: The pathogenesis and etiology of still remain unknown. Current evidence suggests that the occurrence of depression may be related to a reduced secretion of neurotransmitters, neuronal apoptosis, inflammation, intestinal flora and other factors. Although the commonly used antidepressants such as SSRIs, SNRIs, NaSSA, and SARIs produce some therapeutic effects, they fail to relieve the...
European Archives of Psychiatry and Clinical Neuroscience April 18, 2016 Kenji Hashimoto, Takeharu Kakiuchi, Hiroyuki Ohba et al. 125 citations
R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to esketamine (S-ketamine), since it might be free of psychotomimetic side effects. Using [11C]raclopride and positron emission tomography (PET), we investigated whether esketamine and R-ketamine can affect dopamine D2/3 receptor binding in the conscious monkey brain. A single infusion of esketamine (0.5 mg/kg),...
Biological Psychiatry November 4, 2015 Jaskaran Singh, Maggie Fedgchin, Ella Daly et al. 466 citations
BACKGROUND: The purpose of this study was to assess the efficacy and safety and to explore the dose response of esketamine intravenous (IV) infusion in patients with treatment-resistant depression (TRD). METHODS: This multicenter, randomized, placebo-controlled trial was conducted in 30 patients with TRD. Patients were randomly assigned 1:1:1 to receive an IV infusion of .20 mg/kg or .40 mg/kg...
Neuropsychopharmacology March 2012 André Schmidt, Rosilla Bachmann, Michael Kometer et al.
Psychotomimetics like the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine and the 5-hydroxytryptamine2A receptor (5-HT(2A)R) agonist psilocybin induce psychotic symptoms in healthy volunteers that resemble those of schizophrenia. Recent theories of psychosis posit that aberrant encoding of prediction errors (PE) may underlie the expression of psychotic symptoms. This study used a...
Clinical Pharmacology & Therapeutics August 2011 Marko A. Peltoniemi, Teijo I. Saari, Nora M. Hagelberg et al.
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at...
Pharmacopsychiatry December 11, 2009 Georgios Paslakis, Morin Gilles, Andreas Meyer‐Lindenberg et al. 66 citations
We intended to assess safety, response to treatment and time to response of 1.25 mg/kg oral S-ketamine as add-on to standard antidepressants in four depressed patients. Two patients with melancholic depression responded early and stayed in remission, while two patients with distinct somatic symptoms, chronicity or atypical features did not respond. The limited number of patients does not allow...
The World Journal of Biological Psychiatry 2009 Robert Paul, Nadine Schaaff, Frank Padberg et al.
Recent studies with intravenous infusion of the NMDA receptor antagonist ketamine showed robust and rapid antidepressant effects within hours after treatment. Ketamine is a racemic mixture consisting of two enantiomers, R- and S-ketamine. In contrast to ketamine, S-ketamine is reported to be less prone to psychomimetic side effects, such as derealisation and hallucinations. In this report we...